| Title of Invention | TRAZODONE COMPOSITION FOR ONCE A DAY ADMINISTRATION |
|---|---|
| Abstract | The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders. |
| Full Text | TRAZODONE COMPOSITIQN FOR ONCE A PAY ADMINISTRATION TECHNICAL HELD [0001] The present mention relates to the anti-disseat trazodone and in particular to a once a day mutation of trazodone, and to its use for treating depression and certain sleep disorders. WHATISCLABIEPI8; I. A sustained release phaimaceutical composition for once a day oral (tdminislnitiOfn, the composed comprising; about 15% to about 60% Hy weight trazodone or a derivative thereof, and about 13% to about 85% by weight of a controlled release excipient, wherein iH controlled release exponent adminifilered to a mammals, permits the trazodone or derivative thereof to maintain an plasma concentration from at least about one hour to at least about 24 bouts aptest initial admimatration. WHATISCLABIEPI8; I. A sustained release phaimaceutical composition for once a day oral (tdminislnitiOfn, the composed comprising; about 15% to about 60% Hy weight trazodone or a derivative thereof, and about 13% to about 85% by weight of a controlled release excipient, wherein iH controlled release exponent adminifilered to a mammals, permits the trazodone or derivative thereof to maintain an plasma concentration from at least about one hour to at least about 24 bouts aptest initial admimatration. WHATISCLABIEPI8; I. A sustained release phaimaceutical composition for once a day oral (tdminislnitiOfn, the composed comprising; about 15% to about 60% Hy weight trazodone or a derivative thereof, and about 13% to about 85% by weight of a controlled release excipient, wherein iH controlled release exponent adminifilered to a mammals, permits the trazodone or derivative thereof to maintain an plasma concentration from at least about one hour to at least about 24 bouts aptest initial admimatration. |
|---|
1172-CHENP-2008 AMENDED PAGES OF SPECIFICATION 06-09-2013.pdf
1172-CHENP-2008 AMENDED CLAIMS 29-10-2013.pdf
1172-CHENP-2008 AMENDED CLAIMS 06-09-2013.pdf
1172-CHENP-2008 CORRESPONDENCE OTHERS 05-12-2013.pdf
1172-CHENP-2008 CORRESPONDENCE OTHERS 29-10-2013.pdf
1172-CHENP-2008 CORRESPONDENCE OTHERS 27-02-2013.pdf
1172-CHENP-2008 EXAMINATION REPORT REPLY RECEIVED 20-12-2013.pdf
1172-CHENP-2008 EXAMINATION REPORT REPLY RECEIVED 06-09-2013.pdf
1172-CHENP-2008 FORM-1 06-09-2013.pdf
1172-CHENP-2008 FORM-13 29-10-2013.pdf
1172-CHENP-2008 FORM-13 06-09-2013.pdf
1172-CHENP-2008 FORM-3 06-09-2013.pdf
1172-CHENP-2008 FORM-6 12-03-2012.pdf
1172-CHENP-2008 OTHER PATENT DOCUMENT 06-09-2013.pdf
1172-CHENP-2008 OTHERS 06-09-2013.pdf
1172-CHENP-2008 POWER OF ATTORNEY 12-03-2012.pdf
1172-CHENP-2008 ASSIGNMENT 12-03-2012.pdf
1172-CHENP-2008 CORRESPONDENCE OTHERS 12-03-2012.pdf
1172-CHENP-2008 OTHERS 20-12-2013.pdf
1172-CHENP-2008 AMENDED CLAIMS 20-12-2013.pdf
1172-CHENP-2008 AMENDED PAGES OF SPECIFICATION 20-12-2013..pdf
1172-chenp-2008-correspondnece-others.pdf
1172-chenp-2008-description(complete).pdf
| Patent Number | 258416 | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 1172/CHENP/2008 | |||||||||||||||||||||||||||
| PG Journal Number | 02/2014 | |||||||||||||||||||||||||||
| Publication Date | 10-Jan-2014 | |||||||||||||||||||||||||||
| Grant Date | 08-Jan-2014 | |||||||||||||||||||||||||||
| Date of Filing | 07-Mar-2008 | |||||||||||||||||||||||||||
| Name of Patentee | ANGELINI LABOPHARM, LLC | |||||||||||||||||||||||||||
| Applicant Address | 202 CARNEGIE CENTER, SUITE 107, PRINCETON NEW JERSEY 08540, USA | |||||||||||||||||||||||||||
Inventors:
|
||||||||||||||||||||||||||||
| PCT International Classification Number | A61K31/496 | |||||||||||||||||||||||||||
| PCT International Application Number | PCT/CA06/01484 | |||||||||||||||||||||||||||
| PCT International Filing date | 2006-09-11 | |||||||||||||||||||||||||||
PCT Conventions:
|
||||||||||||||||||||||||||||